In the Prospective Evaluation of EECP in Congestive Heart Failure (PEECH) trial, EECP improved exercise duration, symptom status, and QOL in patients with mild-to-moderate heart failure who were ...
March 15, 2005 (Orlando) — Results of the Prospective Evaluation of EECP in Congestive Heart Failure (PEECH) trial, announced here during the American College of Cardiology 2005 Annual Scientific ...
Company Invites Congressmen to Local EECP Therapy Centers to Educate Them about How Non-Invasive Treatment Can Save the Healthcare System Millions Vasomedical, Inc. ("Vasomedical") (OTC BB: VASO), a ...
PANAMA CITY, Fla. (WJHG/WECP) - It’s a therapy aimed at relieving chest pain. Dr. Amir R. Haghighat with the Cardiovascular Institute of Northwest Florida explains that while Enhanced External ...
WESTBURY, N.Y.--(BUSINESS WIRE)--March 10, 2006--Vasomedical, Inc. (Nasdaq SC: VASO), a leader in the noninvasive treatment and management of cardiovascular diseases, reconfirmed that the majority of ...
PITTSBURGH, Feb. 27 – Patients with angina (chest pain) and left ventricular dysfunction respond very well to treatment using enhanced external counterpulsation (EECP), with little or no future heart ...
WESTBURY, N.Y., Oct. 31, 2013 /PRNewswire/ -- Vasomedical, Inc. (" Vasomedical") (OTC BB: VASO), a diversified medical technology company specializing in the design, manufacture and sale of medical ...
Vasomedical, Inc. (NASDAQSmallCap: VASO), announced today that five major third-party payers in the United Kingdom have expanded their reimbursement structures to include EECP external ...
In a small study of long COVID-19 patients, those with and without coronary artery disease demonstrated improvement of a variety of symptoms, including fatigue, breathing difficulties and chest ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results